GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Kimia Biosciences Ltd (BOM:530313) » Definitions » Cash Flow from Operations

Kimia Biosciences (BOM:530313) Cash Flow from Operations : ₹0.00 Mil (TTM As of . 20)


View and export this data going back to 2017. Start your Free Trial

What is Kimia Biosciences Cash Flow from Operations?

Cash flow from operations refers to the cash brought in through a company's normal business operations. It is the cash flow before any investment or financing activities. It is the cash version of net income.

For the six months ended in . 20, Kimia Biosciences's Net Income From Continuing Operations was ₹0.00 Mil. Its Depreciation, Depletion and Amortization was ₹0.00 Mil. Its Change In Working Capital was ₹0.00 Mil. Its cash flow from deferred tax was ₹0.00 Mil. Its Cash from Discontinued Operating Activities was ₹0.00 Mil. Its Asset Impairment Charge was ₹0.00 Mil. Its Stock Based Compensation was ₹0.00 Mil. And its Cash Flow from Others was ₹0.00 Mil. In all, Kimia Biosciences's Cash Flow from Operations for the six months ended in . 20 was ₹0.00 Mil.


Kimia Biosciences Cash Flow from Operations Historical Data

The historical data trend for Kimia Biosciences's Cash Flow from Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kimia Biosciences Cash Flow from Operations Chart

Kimia Biosciences Annual Data
Trend
Cash Flow from Operations

Kimia Biosciences Semi-Annual Data
Cash Flow from Operations

Kimia Biosciences Cash Flow from Operations Calculation

Cash flow from operations refers to the cash brought in through a company's normal business operations. It is the cash flow before any investment or financing activities. It is the cash version of net income.

Kimia Biosciences's Cash Flow from Operations for the fiscal year that ended in . 20 is calculated as:

Kimia Biosciences's Cash Flow from Operations for the quarter that ended in . 20 is:


For stock reported annually, GuruFocus uses latest annual data as the TTM data. Cash Flow from Operations for the trailing twelve months (TTM) ended in . 20 was ₹0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Kimia Biosciences  (BOM:530313) Cash Flow from Operations Explanation

For companies reported in indirect method, cash flow from operations contains six items:

1. Net Income From Continuing Operations:
Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Kimia Biosciences's net income from continuing operations for the six months ended in . 20 was ₹0.00 Mil.

2. Depreciation, Depletion and Amortization:
Depreciation is a present expense that accounts for the past cost of an asset that is now providing benefits.
Depletion and amortization are synonyms for depreciation.
Generally:
The term depreciation is used when discussing man made tangible assets
The term depletion is used when discussing natural tangible assets
The term amortization is used when discussing intangible assets

Kimia Biosciences's depreciation, depletion and amortization for the six months ended in . 20 was ₹0.00 Mil.

3. Change In Working Capital:
Working Capital is a measure of a company's short term liquidity or its ability to cover short term liabilities. It is defined as the difference between a company's current assets and current liabilities. Changes in Working Capital is reported in the cash flow statement since it is one of the major ways in which net income can differ from operating cash flow.

Kimia Biosciences's change in working capital for the six months ended in . 20 was ₹0.00 Mil. It means Kimia Biosciences's working capital {id_Q12} from . 20 to . 20 .

4. Deferred Tax:
It is the cash flow generated from deferred tax.

Kimia Biosciences's cash flow from deferred tax for the six months ended in . 20 was ₹0.00 Mil.

5. Cash from Discontinued Operating Activities:
Net cash from all of the entity's discontinued operating activities.

Kimia Biosciences's cash from discontinued operating Activities for the six months ended in . 20 was ₹0.00 Mil.

6. Asset Impairment Charge:
It is the charge against earnings resulting from the aggregate write down of all assets from their carrying value to their fair value.

Kimia Biosciences's asset impairment charge for the six months ended in . 20 was ₹0.00 Mil.

7. Stock Based Compensation:
It is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Kimia Biosciences's stock based compensation for the six months ended in . 20 was ₹0.00 Mil.

8. Cash Flow from Others:
These are cash differences caused by the change of inventory, accounts payable, accounts receivable etc. For instance, if a company pays its suppliers slower, its cash position will build up faster. If a company receives payments from its customers slower, its account receivables will rise, and its cash position will grow more slowly (or even shrink).

Kimia Biosciences's cash flow from others for the six months ended in . 20 was ₹0.00 Mil.


Kimia Biosciences Cash Flow from Operations Related Terms

Thank you for viewing the detailed overview of Kimia Biosciences's Cash Flow from Operations provided by GuruFocus.com. Please click on the following links to see related term pages.


Kimia Biosciences (BOM:530313) Business Description

Traded in Other Exchanges
N/A
Address
Netaji Subhash Place, 974, 9th Floor, Aggarwal Millenium Tower-II, Pitampura, New Delhi, IND, 110 034
Kimia Biosciences Ltd is a company engaged in the manufacturing of bulk drugs. Some of the company's products include Azelnidipine, Deflazacort, Oxaceprol, Seratodast, and Tretinoin among others. Its only operating segment being Pharmaceuticals.

Kimia Biosciences (BOM:530313) Headlines

No Headlines